In-vitro Activity of Tedizolid and Comparator Agents Against Clinical Gram-positive Isolates Recovered From Patients With Cancer

A total of 248 Gram-positive isolates from cancer patients were tested for in-vitro susceptibility to tedizolid and 3 comparator agents using CLSI broth microdilution methodology. Tedizolid inhibited 97% of isolates at ≤0.5μg/ml. It was active against all Gram-positive species and consistently had 8 fold lower MICs than linezolid, although based on % susceptibility using CLSI breakpoints, most isolates were also susceptible to the comparators. Tedizolid was active against MRSA isolates with vancomycin MICs of ≥ 1.0μg/ml.
Source: Diagnostic Microbiology and Infectious Disease - Category: Microbiology Authors: Tags: Note Source Type: research